EFFECT OF METHYL-Î’-CYCLODEXTRIN COMPLEXATION ON THE HYPOGLYCEMIC AND HYPOLIPIDEMIC EFFECTS OF KHELLIN: EXPERIMENTAL STUDY
Keywords:Khellin, Cyclodextrin complexation, Methyl-beta-cyclodextrin Hypoglycemic effect, Hypolipidemic effect
Objective: The present work tackled the development and evaluation of inclusion complex of khellin (KH) and methyl-Î²-cyclodextrin (MÎ²CD). In addition, it tested its possible hypoglycemic and hypolipidemic effects.
Methods: Inclusion complexes of KH-MÎ²CD in the presence of water-soluble polymer were prepared by freeze drying (FD), co-evaporation (EV) and kneading methods (KN). The selected ternary complex was characterized by Fourier transform infrared spectrophotometry (FTIR), x-ray diffractometry (XRD), differential scanning calorimetry (DSC) and scanning electron microscopy . Assessment of the hypoglycemic effect of the selected ternary complex versus the standard drug metformin was studied. Two different doses of the ternary complex were administered orally to streptozotocin (STZ)-induced type 2diabetic rats. Their hypoglycemic and hypolipidemic effects were evaluated by measuring the fasting blood glucose level (BGL), total cholesterol (TC) and triglycerides levels (TG) along the study period.
Results: The FD complex showed the highest drug dissolution rate. All the performed characterization analysis confirmed the formation of a KH-MÎ²CD inclusion complex. The in vivo study declared that both doses showed a marked hypoglycemic and hypolipidemic effects compared to metformin.
Conclusion: In conclusion, this study points for the first time that the complexation of KH with MÎ²CD could notably improve the dissolution rate and hence the bioavailability of KH. Moreover, this study demonstrated that this compound has a hypoglycemic and hypolipidemic effect. Thus, it can be a promising natural supportive treatment in type 2 diabetes mellitus (T2DM).Â
Elbary A, Kassem M, Abou-Samra M, Khalil R. Formulation and hypoglycemic activity of pioglitazone-cyclodextrin inclusion complexes. Drug Discoveries Ther 2008;2:94-107.
Rogers Foy JM, Powers DL, Brosnan DA, Barefoot SF, Friedman RJ, LaBerge M. Hydroxyapatite composites designed for antibiotic drug delivery and bone reconstruction: a caprine model. J Investigative Surgery 1999;12:263-75.
Berna G, Oliveras-Lopez MJ, Jurado-Ruiz E, Tejedo J, Bedoya F, Soria B, et al. Nutrigenetics and nutrigenomics insights into diabetes etiopathogenesis. Nutrients 2014;6:5338-69.
Sireesha K, Sailaja RP. Oxidative stress and diabetes: an overview. Asian J Pharm Clin Res 2015;8:15-9.
Rabiyamma SC, HUSSAIN PS. Anti-hyperglycemic effect of a hydro-alcoholic extract of thunbergia fragrans in experimental diabetes. Int J Curr Pharm Res 2015;7:38-42.
Saengboonmee C, Seubwai W, Wongkham C, Wongkham S. Diabetes mellitus: possible risk and promoting factors of cholangiocarcinoma: association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol 2015;39:274-8.
Dhaliwall C, Erinmacpherson, Richardson J. Effectiveness of telephone-delivered interventions for increasing physical activity levels in persons with type 2 diabetes or hypertension: a systematic review. J Crit Rev 2015;2:6-11.
Aguiar EJ, Morgan PJ, Collins CE, Plotnikoff RC, Callister R. Characteristics of men classified at high-risk for type 2 diabetes mellitus using the AUSDRISK screening tool. Diabetes Res Clin Pract 2015;108:45-54.
Ragavan B, Krishnakumari S. Antidiabetic effect ofT. arjuna bark extract in alloxan induced diabetic rats. Indian J Clin Biochem 2006;21:123-8.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
Lesniowska J, Schubert A, Wojna M, Skrzekowska-Baran I, Fedyna M. Costs of diabetes and its complications in Poland. Eur J Health Econ 2014;15:653-60.
Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism 2014;63:1480-90.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37-43.
Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am 2015;99:87-106.
Lupascu FG, Dash M, Samal SK, Dubruel P, Lupusoru CE, Lupusoru RV, et al. Development, optimization and biological evaluation of chitosan scaffold formulations of new xanthine derivatives for the treatment of type-2 diabetes mellitus. Eur J Pharm Sci 2015;77:122-34.
Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPA Rgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012;23:205-15.
Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821-7.
Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug Delivery 2015;25:1-20.
Sorli C. New developments in insulin therapy for type 2 diabetes. Am J Med 2014;127:S39-48.
Huang M, Wang F, Zhou X, Yang H, Wang Y. Hypoglycemic and hypolipidemic properties of polysaccharides from Enterobacter cloacae Z0206 in KKAy mice. Carbohydrate Polymers 2015;117:91-8.
Singh SK, Kesari AN, Gupta RK, Jaiswal D, Watal G. Assessment of antidiabetic potential of cynodon dactylon extract in streptozotocin diabetic rats. J Ethnopharmacol 2007;114:174-9.
Rupeshkumar M, Kavitha K, Haldar P. Role of herbal plants in the diabetes mellitus therapy: an overview. Int J Appl Pharm 2014;6:1-3.
Vanachayangkul P, Byer K, Khan S, Butterweck V. An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells. Phytomedicine 2010;17:653-8.
Vanachayangkul P, Chow N, Khan SR, Butterweck V. Prevention of renal crystal deposition by an extract of ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats. Urol Res 2011;39:189-95.
Abu-Hashem AA, Youssef MM. Synthesis of new visnagen and khellin furochromone pyrimidine derivatives and their anti-inflammatory and analgesic activity. Molecules 2011;16:1956-72.
Atta SM, Farrag DS, Sweed AM, Abdel-Rahman AH. Preparation of new polycyclic compounds derived from benzofurans and furochromones. An approach to novel 1,2,3-thia-, and selena-diazolofurochromones of anticipated antitumor activities. Eur J Med Chem 2010;45:4920-7.
Ragab FA, El-Sayed NA, Eissa AA, El Kerdawy AM. Synthesis and anticonvulsant activity of certain substituted furochromone, benzofuran and flavone derivatives. Chem Pharm Bull 2010;58:1148-56.
Jouad H, Maghrani M, Eddouks M. Hypoglycemic effect of aqueous extract of Ammi visnaga in normal and streptozotocin-induced diabetic rats. J Herb Pharmacother 2002;2:19-29.
Sharma N, Baldi A. Exploring versatile applications of cyclodextrins: an overview. Drug Delivery 2014;23:1-19.
Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 2005;6:E329-57.
Yang LJ, Ma SX, Zhou SY, Chen W, Yuan MW, Yin YQ, et al. Preparation and characterization of inclusion complexes of naringenin with beta-cyclodextrin or its derivative. Carbohydr Polym 2013;98:861-9.
Qiu N, Cheng X, Wang G, Wang W, Wen J, Zhang Y, et al. Inclusion complex of barbigerone with hydroxypropyl-beta-cyclodextrin: preparation and in vitro evaluation. Carbohydr Polym 2014;101:623-30.
Miro A, Quaglia F, Sorrentino U, La Rotonda MI, D'Emmanuele Di Villa Bianca R, Sorrentino R. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations. Eur J Pharm Sci 2004;23:57-64.
Gidwani B, Vyas A. Synthesis, characterization, and application of epichlorohydrin-beta-cyclodextrin polymer. Colloids Surf B 2014;114:130-7.
Chowdary KP, Srinivas SV. Influence of hydrophilic polymers on celecoxib complexation with hydroxypropyl-beta-cyclodextrin. AAPS PharmSciTech 2006;7:79.
Chadha R, Bala M, Arora P, Jain DV, Pissurlenkar RR, Coutinho EC. Valsartan inclusion by methyl-beta-cyclodextrin: thermodynamics, molecular modelling, Tween 80 effect, and evaluation. Carbohydr Polym 2014;103:300-9.
Vrzal R, Frauenstein K, Proksch P, Abel J, Dvorak Z, Haarmann-Stemmann T. Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells. PLoS One 2013;8:e74917.
Higuchi TaC KA. Phase-solubility techniques. Adv Anal Chem Instrum 1965;4:95.
Dos Santos C, Buera MP, Mazzobre MF. Phase solubility studies and stability of cholesterol/beta-cyclodextrin inclusion complexes. J Sci Food Agric 2011;91:2551-7.
Dias R, de Azevedo WF Jr. Molecular docking algorithms. Curr Drug Targets 2008;9:1040-7.
Wu G, Robertson DH, Brooks CL, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003;24:1549-62.
Malladi M, Jukanti R, Nair R, Wagh S, Padakanti HS, Mateti A. Design and evaluation of taste masked dextromethorphan hydrobromide oral disintegrating tablets. Acta Pharm 2010;60:267-80.
Aman RM, Meshali MM, Abdelghani GM. The ion-exchange complex of famotidine: sustained release and taste masking approach of the stable liquid dosage form. Drug Discoveries Ther 2014;8:268-75.
Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet-induced obese rats. Acta Pharmacol Sin 2005;26:575-80.
Vincent S. Antidiabetic, hypolipidemic, and histopathological analysis of zingerone in streptozotocin-induced diabetic rats. Asian J Pharm Clin Res 2016;9:220-24.
Deeb A, El-Eraky W, El-Awdan S, Mahgoub S. Pyridazine and its related compounds. Part 34. Hypoglycemic and hypolipidemic activity of some novel condensed pyridazine sulfonamides. Med Chem Res 2014;23:34-41.
Mura P, Faucci MT, Bettinetti GP. The influence of polyvinylpyrrolidone on naproxen complexation with hydroxy-propyl-beta-cyclodextrin. Eur J Pharm Sci 2001;13:187-94.
de Freitas MR, Rolim LA, Soares MF, Rolim-Neto PJ, de Albuquerque MM, Soares-Sobrinho JL. Inclusion complex of methyl-beta-cyclodextrin and olanzapine as a potential drug delivery system for schizophrenia. Carbohydr Polym 2012;89:1095-100.
Zhou Q, Wei X, Dou W, Chou G, Wang Z. Preparation and characterization of inclusion complexes formed between baicalein and cyclodextrins. Carbohydr Polym 2013;95:733-9.
Zoppi A, Delrivo A, Aiassa V, Longhi MR. Binding of sulfamethazine to beta-cyclodextrin and methyl-beta-cyclodextrin. AAPS PharmSciTech 2013;14:727-35.
Barbosa JA, Zoppi A, Quevedo MA, de Melo PN, de Medeiros AS, Streck L, et al. Triethanolamine stabilization of methotrexate-beta-cyclodextrin interactions in ternary complexes. Int J Mol Sci 2014;15:17077-99.
Gera S, Cheruvu S, Zakkula A, SS. Synthesis and evaluation of olmesartan medoxomil complex with sbe7 Î²-cd for enhanced dissolution and bioavailability. Int J Pharm Pharm Sci 2016;8:333-43.
Modi A, Tayade P. Enhancement of dissolution profile by solid dispersion (kneading) technique. AAPS PharmSciTech 2006;7:68.
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996;85:1017-25.
Yap KL, Liu X, Thenmozhiyal JC, Ho PC. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. Eur J Pharm Sci 2005;25:49-56.
Ribeiro LS, Ferreira DC, Veiga FJ. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with beta-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci 2003;20:253-66.
Calabro ML, Tommasini S, Donato P, Raneri D, Stancanelli R, Ficarra P, et al. Effects of alpha and beta-cyclodextrin complexation on the physicochemical properties and antioxidant activity of some 3-hydroxyflavones. J Pharm Biomed Anal 2004;35:365-77.
Li N, Liu J, Zhao X, Gao Y, Zhang L, Zhang J, et al. Complex formation of ionic liquid surfactant and Î²-cyclodextrin. Colloids Surf A 2007;292:196â€“201.
Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003;5 Suppl 1:S19-27.